Health · 44 views
FLT3 inhibitors trigger ferroptosis, exposing new weakness in acute myeloid leukemia
A study published in Nature Cell Biology reports a new vulnerability in acute myeloid leukemia (AML) that might lead to novel therapies to treat the cancer while minimizing harm to normal cells.
AI Summary
A study in *Nature Cell Biology* identifies a new vulnerability in acute myeloid leukemia (AML). Researchers at Baylor College of Medicine and collaborators examined how drugs that neutralize FLT3 mutations work. FLT3 mutations are among the most common genetic drivers of AML. The study shows that inhibiting FLT3 stops AML cells from dividing and kills them by activating a self‑destruct mechanism called apoptosis. This finding could guide the development of therapies that target leukemia cells while sparing normal cells.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Australian survey reveals 60% eat raw fish or seafood, prompting safety warningsContinue reading
- ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitorsContinue reading
- The invisible global health workforce: Why nurses matter more than everContinue reading
- AI measurements of heart scans more strongly linked to patient survival than clinician measurementsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow